Dr. Henning Schmidt is an expert in Model-Informed Drug Development with over fourteen years of industry experience. His has been supporting projects from target validation in the early phases of drug discovery to study design for post-marketing commitments. During the last years, he has provided decision-making support to drug discovery and development teams in various therapeutic areas, including oncology, dermatology, immunology, respiratory, bone and muscle wasting diseases. This has led to several go/no-go decisions on the progression of novel drugs through their development cycle and successful registrations. Henning greatly enjoys working in all stages of drug discovery and development, supporting project teams through integrative quantitative analyses, targeting informed decision making. He also focuses on development and implementation of novel and creative quantitative pharmacology and pharmacometric approaches. Henning received undergraduate education at Darmstadt University, Germany and SUPELEC in Paris, France. He obtained his PhD in Control Theory and Systems Biology at the Royal Institute of Technology in Stockholm, Sweden. He has worked for Fraunhofer Chalmers Research Center (Gothenburg, Sweden) and Novartis Pharma AG (Basel, Switzerland) prior to founding IntiQuan in 2015.
